Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 2.7% – Time to Sell?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares fell 2.7% during trading on Monday . The stock traded as low as $63.32 and last traded at $63.38. 373,644 shares traded hands during trading, a decline of 72% from the average session volume of 1,326,097 shares. The stock had previously closed at $65.16.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Benchmark restated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Trading Up 1.3 %

The company has a 50 day moving average of $58.39 and a two-hundred day moving average of $54.68. The stock has a market capitalization of $8.01 billion, a PE ratio of 18.90, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock valued at $1,754,451 over the last quarter. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HALO. Vanguard Group Inc. increased its holdings in shares of Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after purchasing an additional 386,618 shares in the last quarter. Snyder Capital Management L P raised its holdings in Halozyme Therapeutics by 2.6% in the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company’s stock worth $199,294,000 after purchasing an additional 105,086 shares during the period. Geode Capital Management LLC boosted its position in Halozyme Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after purchasing an additional 30,901 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Halozyme Therapeutics by 2.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock valued at $92,446,000 after purchasing an additional 47,795 shares during the period. Finally, Northern Trust Corp increased its position in shares of Halozyme Therapeutics by 8.7% in the fourth quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company’s stock valued at $87,386,000 after buying an additional 145,617 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.